Earnings Call · Q4 FY2023·2024-02-27

Q4 23EPS +3.68%·Rev n/aQ3 23EPS 0.00%·Rev n/aQ2 23EPS -14.71%·Rev n/aQ1 23EPS +4.40%·Rev n/a⚠ consensus missing

Tarsus Pharmaceuticals, Inc. TARS

David Nakasone — Head of Investor Relations

Bobby Azamian — Chief Executive Officer and Chairman

Aziz Mottiwala — Chief Commercial Officer

Sesha Neervannan — Chief Medical Officer

Jeff Farrow — Chief Financial Officer

+18.3%1d on move date+18.1% vs SPY3d+15.3%5d+11.2%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more TARS calls or request research access.

More TARS calls Browse calls Request research access